These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 19696778

  • 1. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H.
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [Abstract] [Full Text] [Related]

  • 2. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
    Kato J, Yokota N, Tamaki N, Kariya S, Kita T, Ayabe T, Eto T, Kitamura K.
    Hypertens Res; 2011 Mar; 34(3):331-5. PubMed ID: 21124326
    [Abstract] [Full Text] [Related]

  • 3. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 4. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 5. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K.
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [Abstract] [Full Text] [Related]

  • 6. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M, Okubo S, Mizubayashi R, Isaka N, Machida H, Okamoto S, Hirota H, Takeuchi M, Kato T, Nakatani K, Mizuno O, Miyagawa K, Makino K, Okura T, Dohi Y, Ito M, Kimura G.
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [Abstract] [Full Text] [Related]

  • 7. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
    Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K.
    Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [Abstract] [Full Text] [Related]

  • 9. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M, Chen R, Ide A, Iwanami J, Tomochika H, Tomono Y, Mogi M, Horiuchi M.
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [Abstract] [Full Text] [Related]

  • 10. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.
    Matsui Y, Eguchi K, Ishikawa J, Shimada K, Kario K.
    Am J Hypertens; 2011 Apr; 24(4):466-73. PubMed ID: 21164498
    [Abstract] [Full Text] [Related]

  • 11. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K, Ogihara T, Saruta T, Kuramoto K, REZALT Study Group.
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [Abstract] [Full Text] [Related]

  • 12. Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
    Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Saito I, Shimada K, COLM study investigators.
    Hypertens Res; 2009 Feb; 32(2):163-7. PubMed ID: 19262477
    [Abstract] [Full Text] [Related]

  • 13. Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.
    Ishimitsu T, Ohno E, Nakano N, Furukata S, Akashiba A, Minami J, Numabe A, Matsuoka H.
    Clin Exp Hypertens; 2011 Feb; 33(6):366-72. PubMed ID: 21797795
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients.
    Doi M, Miyoshi T, Hirohata S, Kamikawa S, Usui S, Kaji Y, Sakane K, Ogawa H, Ninomiya Y, Kusachi S.
    Am J Med Sci; 2010 May; 339(5):433-9. PubMed ID: 20234301
    [Abstract] [Full Text] [Related]

  • 15. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
    Uzui H, Morishita T, Nakano A, Amaya N, Fukuoka Y, Ishida K, Arakawa K, Lee JD, Tada H.
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):304-9. PubMed ID: 24288395
    [Abstract] [Full Text] [Related]

  • 16. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
    Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M.
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
    [Abstract] [Full Text] [Related]

  • 17. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
    Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group.
    J Hypertens; 2011 Aug; 29(8):1649-59. PubMed ID: 21610513
    [Abstract] [Full Text] [Related]

  • 18. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
    Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Takahashi H, Tomino Y.
    Kidney Blood Press Res; 2009 Aug; 32(4):239-49. PubMed ID: 19752573
    [Abstract] [Full Text] [Related]

  • 19. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
    Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Fukuda T, Numao T, Shimada K, Kario K.
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104
    [Abstract] [Full Text] [Related]

  • 20. Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions.
    Yamada J, Tomiyama H, Matsumoto C, Yoshida M, Shiina K, Yamashina A.
    J Cardiol; 2008 Apr; 51(2):114-20. PubMed ID: 18522784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.